Insider Transactions in Q1 2023 at Novo Cure LTD (NVCR)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
8,318
-6.84%
|
$623,850
$75.29 P/Share
|
|
Mar 03
2023
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
593
-0.89%
|
$45,068
$76.16 P/Share
|
|
Mar 03
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,505
-2.59%
|
$418,380
$76.16 P/Share
|
|
Mar 03
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,635
-3.7%
|
$1,948,260
$76.16 P/Share
|
|
Mar 03
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
21,421
-5.01%
|
$1,627,996
$76.16 P/Share
|
|
Mar 03
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
7,350
-3.61%
|
$558,600
$76.65 P/Share
|
|
Mar 03
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,808
+9.95%
|
-
|
|
Mar 03
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,986
+9.42%
|
-
|
|
Mar 03
2023
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,182
+13.25%
|
-
|
|
Mar 03
2023
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,766
+14.77%
|
-
|
|
Mar 03
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
11,808
+14.44%
|
-
|
|
Mar 02
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,055
-1.1%
|
$79,125
$75.28 P/Share
|
|
Mar 02
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,213
-0.66%
|
$90,975
$75.28 P/Share
|
|
Mar 02
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
937
-0.94%
|
$70,275
$75.28 P/Share
|
|
Mar 02
2023
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
281
-0.42%
|
$21,075
$75.28 P/Share
|
|
Mar 02
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
4,951
-2.66%
|
$371,325
$75.55 P/Share
|
|
Mar 01
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,923
-1.89%
|
$146,148
$76.36 P/Share
|
|
Mar 01
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,684
-2.6%
|
$127,984
$76.36 P/Share
|
|
Mar 01
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,198
-2.24%
|
$167,048
$76.36 P/Share
|
|
Mar 01
2023
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
755
-1.11%
|
$57,380
$76.36 P/Share
|
|
Mar 01
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,164
-1.16%
|
$164,464
$76.36 P/Share
|
|
Feb 28
2023
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,055
+15.75%
|
-
|
|
Feb 28
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
18,621
+22.33%
|
-
|
|
Feb 28
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,818
+19.51%
|
-
|
|
Feb 28
2023
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
17,755
+33.72%
|
-
|
|
Feb 28
2023
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,992
+18.76%
|
-
|
|
Feb 28
2023
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,125
+15.19%
|
-
|
|
Feb 28
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,653
+10.39%
|
-
|
|
Jan 06
2023
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
150
+0.87%
|
$9,300
$62.3 P/Share
|
|
Jan 06
2023
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
108
+0.19%
|
$6,696
$62.3 P/Share
|
|
Jan 06
2023
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98
+0.34%
|
$6,076
$62.3 P/Share
|
|
Jan 06
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
102
+0.06%
|
$6,324
$62.3 P/Share
|
|
Jan 06
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66
+0.09%
|
$4,092
$62.3 P/Share
|
|
Jan 06
2023
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39
+0.29%
|
$2,418
$62.3 P/Share
|
|
Jan 05
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
387
-0.47%
|
$41,796
$108.0 P/Share
|
|
Jan 05
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
39,507
-8.32%
|
$4,464,291
$113.0 P/Share
|
|
Jan 05
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
35,209
+11.66%
|
$528,135
$15.06 P/Share
|
|
Jan 05
2023
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
8,143
-4.26%
|
$952,731
$117.0 P/Share
|
|
Jan 05
2023
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,946
+3.82%
|
$91,462
$47.04 P/Share
|
|
Jan 05
2023
|
Asaf Danziger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
212,500
-19.01%
|
$24,437,500
$115.25 P/Share
|
|
Jan 05
2023
|
Asaf Danziger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
212,500
+43.79%
|
$1,912,500
$9.31 P/Share
|